key: cord-0827969-3knl9k68 authors: Wang, Haizhou; Qiu, Peishan; Liu, Jing; Wang, Fan; Zhao, Qiu title: The liver injury and gastrointestinal symptoms in patients with Coronavirus Disease 19: a systematic review and meta-analysis date: 2020-05-12 journal: Clin Res Hepatol Gastroenterol DOI: 10.1016/j.clinre.2020.04.012 sha: ea367b31a6363d4b484b17c54a54bf9db9774ec4 doc_id: 827969 cord_uid: 3knl9k68 Abstract Backgrounds: Since December 2019, novel coronavirus (SARS-CoV-2)-infected pneumonia (COVID-19) occurred in Wuhan, and rapidly spread throughout China. Our study aimed to evaluate the association of liver injury and gastrointestinal symptoms (GIS) with the progression of COVID-19. Methods: A comprehensive search was performed on the PubMed to identify eligible studies that summarized the liver injury and GIS in COVID-19. Results: A total of 21 studies with 3024 patients were included. Up to 53% patients had liver dysfunctions and the degree of liver damage was associated the severity of the disease. The prevalence of diarrhoea, nausea/vomiting or abdominal pain in patients with COVID-19 were 9.1%, 5.2% and 3.5%, respectively. No significant was found in the prevalence of diarrhoea (OR, 1.24; 95%CI, 0.90 to 1.72; I2 = 0%, p = 0.19) and nausea/vomiting (OR, 1.24; 95%CI, 0.57 to 2.69; I2 = 61%, p = 0.58) between severe and non-severe patients. In addition, diarrhoea (OR, 1.22; 95%CI, 0.50 to 2.98; I2 = 0%, p = 0.66) and nausea/vomiting (OR, 1.09; 95%CI, 0.46 to 2.62; I2 = 0%, p = 0.84) were not associated with the prognosis of COVID-19 patients. Conclusions: The incidences of GIS in patients with COVID-19 is relatively low and are not associated with the COVID-19 progression. Gastroenterologists should pay more attention to the liver injury induced by SARS-CoV-2 during the course of infection. Since December 2019, novel coronavirus (SARS-CoV-2)-infected pneumonia occurred in Wuhan and spread rapidly across the world [1, 2] . The pathogen was confirmed to be a distinct clade from the β-coronaviruses, which was officially named SARS-CoV-2 with the disease termed COVID- 19 . Liver injury has been reported in several recent COVID-19 studies, but its incidence varies [3, 4] . In addition, Gu et al and Xiao et al concluded that gastrointestinal symptoms (GIS) (diarrhoea, vomiting or abdominal pain) should not be ignored during the outbreak of COVID-19 [5, 6] . Song et al also reported a case with diarrhoea as the onset symptom, and emphasized that gastrointestinal system might be a potential route for SARS-CoV-2 infection [7] . However, the latest epidemiological study showed a relatively low prevalence of gastrointestinal symptoms induced by SARS-CoV-2 [3] . Therefore, we performed a systematic review and meta-analysis to determine the liver injury and the prevalence of GIS in COVID-19 patients. This meta-analysis was performed and reported according to the PRISMA statement [8] . The study was approved by the Ethics Committee of the Zhongnan Hospital of Wuhan University (No. 2020011). A literature search was performed on the PubMed library from inception to 31 March 2020. The search strategy was a combination of ("COVID-19" OR "2019-ncov" OR "SARS-CoV-2") AND ("clinical features" OR "clinical characteristics"). The relevant papers were also searched manually to identify additional studies that might have been missed in the above literature search. A PICOS criteria was applied to strict the inclusion and exclusion criteria. Inclusion criteria were as follows: 1) studies about clinical characteristics of COVID-19; 2) number of samples The data were extracted independently by two authors (Haizhou Wang and Fan Wang) from the included studies based on the following terms: 1) study ID, 2) date, 3) group size, 4) patient demographics, 5) group design, 6) liver dysfunction, including ALT/AST/ALB/GLB/TB, 7) GIS, including abdominal pain, diarrhoea and nausea or vomiting. Discrepancies would be solved through discussion. The Cochrane Review Manager (RevMan) program (RevMan 5.3, Denmark) and OpenMeta Analyst were used to pool and analyze the aforementioned outcomes extracted from the included studies. For the AEs (dichotomous data), odds ratios (OR) with 95% confidence intervals (CI) were selected to report the risk estimates following the Mantel-Haenszel method [9] . In addition, the heterogeneity among the studies we included was assessed by the Q and I 2 statistic [10] . When I 2 < 50%, the fixed effects model was applied to estimate risk using the DerSimonian and Laird method because of lower heterogeneity. In contrast, the random effects model was used when I 2 was > 50% [9] . A p value < 0.05 was considered to be statistically significant. Figure 1 showed the search flowchart and twenty-one studies were included with a total of 3024 COVID-19 patients [3, 5, [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] . The baseline characteristics of the included studies was presented in Table 1 . First, we evaluated how the liver is affected based on the included study. A total of 16 studies reported liver comorbidities or ALT/AST/ALB/GLB/TB abnormalities ( Table 2 ). The data showed that 0.8-11% of COVID-19 patients had chronic liver comorbidities and 2.6-53% patients had abnormal levels of ALT, AST and TB, and 6-98% had abnormal levels of ALB during the COVID-19 progression. Moreover, patients with severe conditions or nonsurvival patients had higher rates of liver dysfunction. Thus, liver injury was more common in severe cases than mild cases in COVID-19. Diarrhoea was the most common gastrointestinal symptom (19 studies included symptoms of diarrhoea) and selected as the primary outcome, while its prevalence was only 9.1% (95%CI, 6.3% to 11.9%, Fig. 2a) . Fourteen studies reported symptoms of nausea or vomiting, with the prevalence of 5.2% (95%CI, 3.5% to 7.0%, Fig. 2b ). In addition, only four studies reported abdominal pain, with the prevalence of 3.5% (95%CI, 1.7% to 5.4%, Fig. 2c ). We then compared the prevalence of GIS between severe and non-severe patients. The definition of severe and non-severe also includes intensive care unit (ICU) vs. non-ICU and generally vs. refractory. Seven studies were included, and the results showed that no significant was found in the prevalence of diarrhoea between severe and non-severe patients (OR, 1.24; 95%CI, 0.90 to 1.72; I 2 = 0%, p = 0.19) (Fig. 3a) . In addition, the severe patients also 6 had similar prevalence of nausea or vomiting with non-severe patients (OR, 1.24; 95%CI, 0.57 to 2.69; I 2 = 61%, p = 0.58) (Fig. 3b) . The relationship between GIS and prognosis of COVID-19 was also analyzed. Three studies were included, and the results also indicated that diarrhoea was not associated with the prognosis of COVID-19 patients (OR, 1.22; 95%CI, 0.50 to 2.98; I 2 = 0%, p = 0.66) (Fig. 4a) . The results also showed no significant difference in the prevalence of nausea/vomiting between non-survival and survival patients (OR, 1.09; 95%CI, 0.46 to 2.62; I 2 = 0%, p = 0.84) (Fig. 4b) . In this study, we found that the prevalence of diarrhoea, nausea/vomiting, and abdominal pain in COVID-19 patients was 9.1%, 5.2%, and 3.5%, respectively. Meanwhile, they were not associated with the disease progression and patient prognosis. However, liver damage caused by SARS-CoV-2 infection was associated with disease progression. Diarrhoea is the most common GIS in coronavirus infections, while nausea and vomiting are not specific. Moreover, nausea and vomiting are not necessarily caused by SARS-COV-2 infection and may be the result of various system dysfunctions. Therefore, diarrhea is the focus symptom of gastroenterologists on patients with coronavirus infection. It was reported that the prevalence of diarrhoea in patients with Middle East Respiratory Syndrome (MERS) and SARS was 30% and 10.6%, respectively [29] . One study indicated that MERS coronavirus could survive in simulated gastrointestinal fluids and has the ability to infect intestinal organoid models [29] . Hui et al also proposed that SARS-CoV can be transmitted through the fecal-oral route [30] . Furthermore, Zhang et al found that in the later stage of SARS-CoV-2 infection, the proportion of positive anal swabs was much higher than that of throat swabs [31] . The prolonged existence of SARS-CoV-2 viral RNA in faecal samples was also observed by Wu et al [32] . They found that 55% of COVID-19 patients had anal swab positive results, and the average positive time of throat swab was 16.7 days, while the average positive time for anal swabs was 27.9 days. Importantly, positive staining of viral nucleocapsid protein (NP) and angiotensin-converting enzyme 2 (ACE2) could be visualized in the cytoplasm of stomach, duodenum and rectal gland epithelial cells through immunofluorescence [5] . These might provide the basis for virus mutation to obtain fecal-oral transmission capability. However, it is necessary to further identify whether diarrhoea is induced by antiviral drugs or antibiotics. For example, oseltamivir can cause drug-related diarrhoea [33] . Although there are some supportive findings, it is premature to determine whether SARS-CoV-2 can be transmitted through the fecal-oral route based on the current studies. Further well-designed studies are needed to identify the role of SARS-CoV-2 on the gastrointestinal tract. In addition, up to 60% of SARS patients had liver impairment [34] . It was also reported that MERS patients had liver dysfunction [35] . Virus infection of liver cells may be the direct cause of liver damage, and recent study detected SARS-COV-2 RNA in blood samples, which Based on the currently published data, it could be determined that liver injury in patients with mild COVID-19 could return to normal without special treatment, whereas liver injury in severe patients was more severe and required liver protection treatment. This may be due to the impaired immune function of patients with COVID-19. Our data showed 6-98% patients had abnormal ALB level and recent studies also demonstrated that lymphopenia, downregulation of CD4+ lymphocytes and cytokine storm were common in the severe or critical cases [14] . For patients with pre-existing chronic liver disease, such as chronic hepatitis In conclusion, liver injury caused by SARS-CoV-2 virus infection was associated with the severity of the disease. The prevalence of GIS was relatively low and was not associated with disease progression, with diarrhea of 9.1%, nausea/vomiting of 5.2% and 3.5% abdominal pain. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health -The latest 2019 novel coronavirus outbreak in Wuhan, China Clinical features of patients infected with 2019 novel coronavirus in Wuhan Clinical Characteristics of Coronavirus Disease 2019 in China Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study Evidence for gastrointestinal infection of SARS-CoV-2 COVID-19: Gastrointestinal manifestations and potential fecaloral transmission SARS-CoV-2 induced diarrhoea as onset symptom in patient with COVID-19 Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement Percutaneous kyphoplasty for osteoporotic vertebral compression fractures via unilateral versus bilateral approach: A meta-analysis Meta-analysis in clinical trials revisited Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America Clinical characteristics and imaging manifestations of the 2019 novel coronavirus disease (COVID-19):A multi-center study in Wenzhou city Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series Imaging and clinical features of patients with 2019 novel coronavirus SARS-CoV-2 Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study Clinical characteristics of laboratory confirmed positive cases of SARS-CoV-2 infection in Wuhan, China: A retrospective single center analysis. Travel medicine and infectious disease Clinical features of patients infected with 2019 novel coronavirus in Wuhan Clinical Characteristics of Coronavirus Disease 2019 in China. The New England journal of medicine Clinical progression of patients with COVID-19 in Shanghai Epidemiologic and Clinical Characteristics of 91 Hospitalized Patients with COVID-19 in Zhejiang, China: A retrospective, multi-centre case series. QJM : monthly journal of the Association of Physicians Clinical characteristics of refractory COVID-19 pneumonia in Wuhan, China. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America Epidemiologic and Clinical Characteristics of Novel Coronavirus Infections Involving 13 Patients Outside Wuhan, China Epidemiological, clinical characteristics of cases of SARS-CoV-2 infection with abnormal imaging findings CT Imaging Features of 2019 Novel Coronavirus (2019-nCoV) A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster Severe Acute Respiratory Syndrome: Historical, Epidemiologic, and Clinical Features Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes Prolonged presence of SARS-CoV-2 viral RNA in faecal samples. The lancet Gastroenterology & hepatology Oseltamivir, amantadine, and ribavirin combination antiviral therapy versus oseltamivir monotherapy for the treatment of influenza: a multicentre, double-blind, randomised phase 2 trial SARS-associated viral hepatitis caused by a novel coronavirus: report of three cases Histopathology of Middle East respiratory syndrome coronovirus (MERS-CoV) infection -clinicopathological and ultrastructural study None. The levels of ALB decreased below the normal range in the non-survival